Skip to main content

Table 2 NT-proBNP, inflammatory markers, osteoprotegerin and fetuin-A during treatment with vitamin D analogs

From: The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study

  Period 1 Period 2
  Alfacalcidol Paricalcitol Difference between groups Alfacalcidol Paricalcitol Difference between groups
  Week 6 Week 22 Increase Week 6 Week 22 Increase Week 28 Week 44 Increase Week 28 Week 44 Increase
NT-proBNP (pmol/l) median (range) 417.8 (78-19048) N = 26 606.2 (90-63974) 187.7 (-888-44932) 485.4 (79-13543) N = 29 785.5 (39-7766) 300.1 (-12433-6124)* -121.1 (95%CI -429.4 to 187.2) 763.8 (55-2769) N = 29 1005.0 (43-8519) 155.8 (-1917-7680) 497.1 (54-42379) N = 26 487.6 (45-53669) -42.1 (-3262-11290) -429.7 (95%CI -938.1 to 78.8)
Log NT-proBNP 2.74 (0.60) N = 26 6.63 (1.47) 3.89 (0.19)# 2.76 (0.57) N = 29 6.69 (1.22) 3.93 (0.17)# 0.04 (95%CI -0.54 to 0.47) 6.39 (1.07) N = 29 6.73 (1.21) 0.34 (0.19) 6.60 (1.53) N = 26 6.37 (1.49) -0.22 (0.13) -0.56 (95% CI -1.04 to -0.10)¤
hs-Crp (mg/l) median (range) 9.61 (0.3 -28.0) N = 24 6.58 (0.4-73.2) -0.07 (-21-63) 7.23 (0.3-27.7) N = 29 5.30 (0.3-81.0) -0.01 (-21-66) -0.76 (95%CI -5.9 to 4.4) 7.52 (0.6-62.4) N = 29 5.25 (0.2-34.3) -0.31 (-55-11) 6.96 (0.25-48.3) N = 24 5.46 (0.37-60.8) -1.18 (-46- 58) -0.85 (95%CI -4.7 to 3.0)
Log hs-Crp 1.86 (1.20) N = 24 1.80 (1.38) -0.06 (0.21) 1.54 (1.31) N = 29 1.58 (1.54) 0.03 (0.21) 0.09 (95%CI -0.69 to 0.51) 1.70 (1.29) N = 29 1.38 (1.38) -0.32 (0.19) 1.93 (1.26) N = 24 1.67 (1.08) -0.27 (0.27) 0.05 (95%CI -0.60 to 0.71)
IL-6 (pg/ml) 6.99 (5.34) N = 21 7.05 (8.40) 0.06 (1.90) 5.56 (3.68) N = 24 8.34 (14.24) 2.79 (2.64) -2.73 (95%CI -9.47 to 4.01) 6.59 (3.51) N = 21 5.66 (5.21) -0.93 (0.75) 6.11 (3.91) N = 24 5.90 (3.53) -0.21 (1.07) 0.72 (95%CI -1.87 to 3.29)
TNF-α (pg/ml) 6.63 (2.45) N = 23 7.76 (6.16) 1.13 (1.32) 7.05 (2.20) N = 26 6.85 (2.28) -0.21 (0.44) 1.34 (95%CI -1.33 to 4.00) 6.59 (2.36) N = 26 7.18 (3.00) 0.53 (1.32) 6.42 (2.26) N = 23 7.04 (2.19) -1.22 (2.16) - 1.75 (95%CI -6.72 to 3.21)
Fetuin-A (μg/ml) 319.15 (76.41) N = 23 362.92 (77.77) 43.77 (14.07)# 330.81 (81.83) N = 26 340.75 (84.98) 9.93 (9.62) 32.84 (95%CI 0.21 to 67.47) ¤ 331.29 (107.15) N = 26 318.94 (91.32) -12.35 (18.39) 329.55 (81.00) N = 23 299.20 (74.95) -30.35 (22.26) -42.7 (95%CI -75.62 to 33.69)
Osteoprotegerin (pg/ml) 4461.77 (1905.1), N = 22 4878.00 (1954.20) 416.23 (178.52)# 4009.39 (1636.80) N = 26 4442.15 (2147.7) 432.77 (193.65)# 16.54 (95%CI -544.13 to 521.05) 4333.4 (1947.1) N = 26 4567.04 (2003.1) 233.64 (102.55)# 4982.68 (1988.9) N = 22 4911.09 (1874.4) -71.59 (209.52) 305.23 (95%CI -757.83 to 147.36)
  1. Distribution of NT-proBNP and hs-Crp was skewed and analyses were done by Mann-Whitney two sample test and presented with Hodge-Lehman median (95% confidence interval).
  2. Logarithmic transformed NT-proBNP and hs-Crp and the remaining parameters were compared using an unpaired t-test and presented with the mean difference (95% confidence intervals).
  3. *: Wilcoxon signed rank test P<0.05; #: Two-sample paired t-test P < 0.05; ¤: Two-sample unpaired t-test, P < 0.05. Parameters are presented as mean (SD) and differences in mean (SEM) unless specified otherwise.
\